Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Telaprevir phase III retreatment trial in genotype 1 chronic hepatitis C after prior Peg-IFN/ribavirin failure
NL-OMON32876Phase 3Active, not recruiting
- Sponsor
- Janssen Pharmaceutical
- Start
- Dec 2008
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 3, randomised, double-blind trial of telaprevir in hepatitis C virus infection (3 arms), sponsored by Janssen Pharmaceutical. Primary endpoint: Sustained virologic response. Started Dec 2008; status: active, not recruiting.
02
Drugs
telaprevir
03
Conditions
hepatitis C virus infection
Beyond the preview
Go deeper on NL-OMON32876.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NL-OMON32876.